Investing in pharmaceutical companies should consider their pipeline strength over current profits, as temporary sales of blockbuster drugs can impact earnings. Pfizer and AbbVie exemplify this, with Pfizer’s Covid vaccine sales boosting profits temporarily, while AbbVie’s Humira faced generic competition but had new drugs in the pipeline. Companies like Novo Nordisk and Eli Lilly are focusing on weight-loss drugs with additional benefits, while AstraZeneca and Merck are prominent in the cancer drug market. Assessing investment potential, Novo and AstraZeneca offer lower risk, Eli Lilly and AbbVie provide reasonable risk/reward profiles, and Merck poses higher risk due to dependency on Keytruda.
Full Article
Why Is Wall Street So Bullish on Tesla? Here's the $1 Trillion Reason
Dan Ives, an analyst at Wedbush Securities, has set a $500 price target for Tesla (NASDAQ: TSLA), driven by a belief in a $1 trillion opportunity linked to the company's emerging robotaxi business. He emphasizes that Tesla's future valuation largely depends on the success of its autonomous vision, particularly with a significant launch planned in Austin this June. Explain It To Me Like I'm 5: Dan Ives, a smart money expert, believes Tesla's stock could...
Read more